{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT06150157","nct_id":"NCT06150157","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06150157. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"In dose escalation (Part 1), participants will receive JNJ-88549968. For myelofibrosis (MF) participants only, the study will explore a Phase 1b cohort in which the janus kinase (JAK) inhibitor ruxolitinib or momelotinib is started in combination with JNJ-88549968. The dose will be escalated sequentially to determine the recommended phase 2 dose (RP2D) and optimal dosing schedule (s) based on safety, pharmacokinetic, pharmacodynamic, and preliminary assessment of efficacy across several dose regimens. Additional Cohorts may be added to assess different formulation or delivery methods. In dose expansion (Part 2, Part 2b \\[US only\\]), participants will receive JNJ-88549968 at the RP2D regimen(s) determined in dose escalation (Part 1, Part 1b \\[US only\\]).","label":"Dose Escalation (Part 1), Dose Expansion (Part 2) and Part 1b (US only), Part 2b (US only)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-06-14","type":"ESTIMATED"},"conditions":["Neoplasms"],"enrollment":{"count":300,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"JNJ-88549968","otherNames":[],"type":"DRUG"},{"name":"Ruxolitinib","otherNames":[],"type":"DRUG"},{"name":"Momelotinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-04","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ 88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-06-14","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1, Part 1b (US Only): Number of Participants With Dose Limiting Toxicity (DLT)","timeFrame":"Approximately up to 35 days after first dose of study treatment"},{"measure":"Part 1, 2, Part 1b (US Only), Part 2b (US Only): Number of Participants with Adverse Events (AEs)","timeFrame":"Up to 2 years"},{"measure":"Part 1, 2, Part 1b (US Only), Part 2b (US Only): Number of Participants with Adverse Events (AEs) by Severity","timeFrame":"Up to 2 years"}],"references":[],"start_date":{"date":"2023-12-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms","url":"https://clinicaltrials.gov/study/NCT06150157"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06150157"}